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the normal development of lymphocytes and other blood cell lineages, and have an important role
in haematopoietic malignancies. Accumulating data link Ikaros to immune receptor rearrangement
and signaling, and the balance between proliferation and differentiation of immune cells. The
emerging picture is that Ikaros family members are critical for a functional immune system that
confers protection against invading pathogens, while minimising the risk of leukaemic transforma-
tion, immune pathology, and autoimmunity.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Ikaros, lymphocyte development and cancer
Ikaros, the founding member of a family of DNA binding pro-
teins [1–3], is expressed in haematopoietic stem cells, all lymphoid
and some myeloid cells. Like its close relatives Helios and Aiolos,
Ikaros is conﬁned mainly to haematopoietic cells [4,5], whereas
distantly related members of the Ikaros family are more widely ex-
pressed [6,7]. Identiﬁed as a factor that targets the lymphocyte-
speciﬁc genes Dntt [1,3] and Cd3d [2], Ikaros is a zinc ﬁnger protein
with N-terminal DNA binding and C-terminal dimerisation do-
mains [2,3] (Fig. 1a). Ikaros is required for lymphocyte develop-
ment since its deletion abrogates fetal T and B lymphocytes and
perturbs myeloid development [8]. While T-cells develop postna-
tally in Ikaros-deﬁcient mice, B cells remain absent throughout life
[8]. Dominant negative versions of Ikaros that lack DNA binding
but still dimerise with other Ikaros family members have even
more dramatic effects with lymphocytes and their precursors
missing altogether [9] and erythroid and myeloid development
also affected [10]. Interestingly, mice with one disrupted and one
functional copy of Ikaros develop T-cell malignancies [11] and
mutations in IKZF1, the gene encoding Ikaros, occur frequently in
human leukaemias: 84% of Philadelphia chromosome-positive pa-
tients with acute lymphoblastic leukaemia (ALL) of B cell progeni-
tors have IKZF1 deletions at the time of diagnosis, and IKZF1
deletions occur frequently at the progression of chronic myeloid
leukemia to lymphoid blast crisis [12]. Importantly, loss or muta-
tion of IKZF1 correlates with poor clinical outcome [13]. Singlechemical Societies. Published by E
.ac.uknucleotide sequence polymorphisms at the IKZF1 gene correlate
with the incidence of ALL, suggesting variations in Ikaros or its reg-
ulatory elements as a genetic risk factor [14,15].
2. Gene regulation by Ikaros proteins
Despite the importance of Ikaros family proteins for normal hae-
matopoiesis and their prominent role in human leukaemia, only a
handful of direct Ikaros target genes are known. These include
Cd3d [2] Dntt [1], Ig kappa [16] Rag [17,18], Igll1 [19,20], Cd8 [21],
Myc [22], and perhaps other Ikaros family members [23]. Possible
mechanisms by which Ikaros family proteins regulate their targets
include competition with transcriptional activators, recruitment of
chromatin modiﬁers and spatial compartmentalisation within the
nucleus. At the Dntt and Igll1 promoters, Ikaros binding sites over-
lap with sites for the activator proteins Ets1 and Ebf, resulting in
competition for promoter binding [20,24]. Ikaros interacts with
chromatin modiﬁers, such as the Mi2 histone deacetylase [25–
27], linking Ikaros to local chromatin remodelling. On amore global
scale, Ikaros proteins co-localise with silent genes at transcription-
ally repressive compartments in the nucleus, known as pericentro-
meric heterochromatin [24,28,29] (Fig. 1b). Whether Ikaros is
mechanistically involved in recruiting target genes to these com-
partments remains to be tested experimentally.
3. Ikaros in immune receptor rearrangement and signaling
The virtually unlimited proliferative potential of lymphocytes is
essential for a functional immune system, but must be controlled tolsevier B.V. All rights reserved.
Fig. 1. Domain structure and nuclear distribution of Ikaros proteins. (a) Both the
DNA binding and dimerization domains comprise zinc ﬁngers. Exons 4–7 are
alternatively spliced, generating Ikaros isoforms with different DNA binding
abilities. (b) Ikaros forms foci around centromeric heterochromatin where silent,
but not active genes can be found [28,29].
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dence of leukaemias and lymphomas. Lymphocyte proliferation,
differentiation and function are tightly controlled by checkpoints
that ensure successful rearrangement of B- and T-cell receptor
genes. Early evidence indicated hyperactive lymphocyte receptor
signaling in Ikaros- and Aiolos-deﬁcient mice [30–32]. Molecular
dissection suggested a role for Ikaros in the phosphorylation of
phospholipase Cgamma2 and intracellular calcium mobilization
and in the activation of Casitas B lymphoma protein subsequent
to BCR activation [34]. However, as outlined below, the impact of
Ikaros on immune receptor rearrangement and signaling goes far
beyond modulating immune receptor signal strength.
B lymphocytes arise from haematopoietic stem cells through
distinct stages characterised by the expression of marker genes
and the rearrangement of immunoglobulin (Ig) loci reviewed in
[35,36] (Fig. 2a). Igh (heavy) chain rearrangement occurs at the
CD43+ c-kit+ CD25- pro-B cell (also known as pre-BI) stage. Produc-
tive Igh rearrangement allows the expression of a pre-B cell recep-
tor (pre-BCR) consisting of IgH and the surrogate light chain
components k5 and Vpre-B1 (encoded by Igll1 and Vpreb1) to initi-
ate the transition to the CD43 c-kit CD25+ pre-B (also known asFig. 2. Ikaros and pre-BCR sinaling. (a) Development of mature B cells from haematopoie
Ikaros proteins on pre-BCR expression and cell cycle progression in pre-B cells.pre-BII) stage. Pre-BCR signaling results in cell cycle entry and a
transient phase of proliferation (the large pre-BII cell stage). Subse-
quently, the pre-BCR is downregulated and the cells drop out of cy-
cle to initiate Ig light chain rearrangement, which allows the
expression of a BCR and progression to the immature and eventu-
ally the mature B cell stage [reviewed in 35,36]. The earliest known
role for Ikaros within this process is at the level of haematopoietic
stem cells, which depend on Ikaros for their activity [37]. Analysis
of gene expression data from Ikaros deﬁcient progenitors suggests
that Ikaros may affect lineage commitment by shutting down the
expression of stem cell genes and ’priming’ the expression of lym-
phocyte genes [38]. To investigate the essential role of Ikaros in the
emergence of B cell precursors [8,9], Reynaud et al. [18] reconsti-
tuted Ikaros-deﬁcient hematopoietic progenitors with the tran-
scription factor EBF. This allowed the emergence of pro-B cells
that expressed Pax5 and CD19, but these cells failed to recombine
variable gene segments at the Igh locus [18]. Restoration of Ikaros
promoted Igh rearrangements, at least in part by inducing the
expression of recombination-activating genes, and by controlling
the chromatin structure of the Igh locus [18].
The success of IgH chain rearrangement is checked by the for-
mation of a pre-B cell receptor consisting of IgH, k5 and V-preB1
to allow testing of the Ig heavy chain at a time in development
prior to Ig light chain rearrangement. Mutations that disable hu-
man k5 expression abrogate human B-cell development [39]. Sig-
naling through the pre-BCR in the presence of IL-7 drives the
clonal expansion of pre-B cells with successful IgH rearrangements,
and an analogous pre-TCR mediated step expands pre-T cells with
functional Tcrb rearrangements.
Proliferation in response to pre-BCR signaling requires both cy-
clin D3 (Ccnd3) and c-Myc (Myc) [40,41]. The pre-BCR controls the
expression of Myc [43] and stabilises IL-7 receptor-induced cyclin
D3 protein [40,44]. Pre-B cells are a self-renewing population with
virtually unlimited proliferative potential. To control this potential
and to drive the rearrangement of Ig light chains, pre-BCR signaling
must eventually be switched from promoting proliferation to
promoting differentiation. The mechanisms that underlie this
transition are of interest for understanding not only normal lym-
phocyte development, but also the etiology of leukaemias and
lymphomas.
In normal pre-B cells, the impact of pre-BCR signaling is pro-
grammed to change from driving proliferation to differentiation
[45]. Interestingly, pre-B cell receptor signaling results in elevated
expression of the Ikaros family member Aiolos [20]. Aiolos and
Ikaros subsequently cooperate to downregulate the Igll1 andtic stem cells (HSC). (b) Regulation of Aiolos by pre-BCR signaling and the impact of
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B1 [20]. As a result, Ikaros and the Ikaros family member Aiolos en-
sure that pre-BCR signaling terminates pre-BCR expression
(Fig. 2b). In fact, pre-BCR signaling requires Ikaros to induce B cell
differentiation [46]. This suggests that not only does Ikaros regu-
late signaling through lymphocyte receptors, but lymphocyte
receptor signaling can also control the expression of Ikaros family
members. The pre-BCR-to-Aiolos feedback loop depends on a spe-
ciﬁc branch of pre-BCR signaling mediated by the adapter adaptor
protein SH2-domain-containing leukocyte protein of 65 kDa, SLP65
[20]. The interferon regulatory factors 4 and 8 may mediate be-
tween SLP65 and Aiolos [47]. Consistent with a role in the termina-
tion of pre-BCR signaling, patients lacking SLP65 show a block in B-
cell development [48] and SLP65 deﬁciency is associated with en-
hanced pre-B cell proliferation and pre-B-cell leukaemia in mouse
[4] and in human [49]. In addition, Ikaros appears to promote SLP-
65 activation by as yet unknown mechanisms, and is required for
cell cycle arrest in response to pre-BCR signaling [46]. SLP65 also
has a role in promoting Ig kappa rearrangement through a pathway
that involves Foxo transcription factors [50], the interferon regula-
tory factors 4 and 8, which are implicated in regulating Aiolos
expression [47], and perhaps Ikaros itself [16].
Although pre-BCR downregulation is important for normal
B-cell development, it is not essential to terminate pre-B cell pro-
liferation or to initiate Ig light chain rearrangement [51]. Rather,
pre-B cell proliferation stops when IL-7 receptor signaling becomes
limiting and Myc and Ccnd3, two drivers of the pre-BCR-driven
expansion phase discussed above, are downregulated [40,44,52].
Interestingly, just like the pre-BCR components Igll1 and Vpreb1,
Myc and Ccnd3 are also targets of this feedback loop, since Ikaros
and Aiolos downregulate Myc [22] and Ccnd3 [52] expression
(Fig. 2b). To settle the debate which of these effects are direct
and which are indirect [22], it will be important to analyse gene
expression downstream of Ikaros proteins independently of (or
prior to) cell cycle arrest. Nevertheless, consistent with a role for
Aiolos in limiting pre-B cell proliferation, there are increased num-
bers of pre-B cells in Aiolos-deﬁcient mice [53].
The relevance of Ikaros proteins for the termination of human
pre-B cell proliferation is underscored by the seminal ﬁnding that
IKZF1, the gene encoding Ikaros, is mutated in most ALL cases
[12,13]. Whether the Ikaros targets identiﬁed to date can account
for its importance for lymphocyte development, cell cycle regula-
tion, and cancer remains to be seen.4. Ikaros and developmental decisions in the immune system
Following the rearrangement of T- and B-cell receptors, signal-
ing through these receptors determines the further differentiation
of T- and B-cells. Checkpoints eliminate self-reactive BCR and TCR
speciﬁcities (negative selection) and direct the differentiation of
thymocytes into mature CD4 helper or CD8 cyctotoxic T cells (po-
sitive selection). Genetic experiments suggest that the Ikaros fam-
ily member Ailos modulates the strength of Ig signaling and
thereby inﬂuences the differentiation of B cells into follicular of
marginal zone B cells [32], immunoglobulin isotype selection
[54], and the generation of high afﬁnity bone marrow plasma cells
[55]. In the thymus, TCR signaling drives the differentiation of
immature CD4 CD8 double positive thymocytes towards the alter-
native CD4 and CD8 T cell fates, and Ikaros appears to inﬂuence
this choice [56,57]. Once T cells have left the thymus and reside
in peripheral lymphoid organs, their further differentiation de-
pends on TCR signaling, which again may be modulated by Ikaros
[31]. Speciﬁcally, Ikaro family members have been linked to the
choice between T cell activation, anergy and tolerance by regulat-
ing the production of IL-2 [26,58] and IL-10 [59], the specializationof naive T helper (Th) cells into Th1 [60] or Th2 cells [61], and the
differentiation and function of regulatory T cells [62].
Peripheral tolerance works by only allowing full activation of
those T cells that receive TCR signals in an appropriate context.
The acquisition of effector functions typically requires co-stimula-
tory signals, which are often regulated by the innate immune sys-
tem as indicators that pathogens are present. Signaling through the
TCR alone promotes anergy, a state where T cell activation is short-
lived and does not lead to effector cell differentiation. The T cell
growth factor IL-2 is a critical determinant of the balance between
activation and anergy. Bandyopadhyay et al. [26] observed that
histone acetylation (an ’activating’ chromatin mark) was reduced
at the Il2 locus in anergic T cells and proposed that Ikaros was
important to bring this about by recruiting histone deacetylases
to the locus. Similarly, Thomas et al. [58] reported that without
Ikaros, co-stimulatory signals are no longer required for IL-2 pro-
duction, and that Ikaros is required for the induction of anergy in
CD4 + T cells.
Foxp3, the signature transcription factor of regulatory T cells, si-
lences numerous target genes involved in immune responsiveness,
and this ability has been attributed to the Ikaros family member
Eos [62]. Eos interacts directly with Foxp3, and Eos knockdown
abrogates the ability of regulatory T cells to suppress immune re-
sponses [62]. Helios is speciﬁcally expressed in regulatory T cells
that arise in peripheral lymphoid organs [63,64].
Despite these observations in T cells, the manifestations of
autoimmunity in Ikaros and Aiolos-deﬁcient mice appear to be lar-
gely mediated by antibodies, which are produced by B cells. Over-
active B cells and symptoms similar to the antibody-mediated
autoimmune disease Lupus erythematodes are common in Aio-
los-deﬁcient mice [32,65] and depend on OBF-1, a transcription
that appears to be regulated by Aiolos [65]. Ikaros also controls
the release of IL-4 from mast cells, which affects the course of
EAE, an experimental model of multiple sclerosis [66].
The differentiation of plasmacytoid dendritic cells, but not other
dendritic cell, is blocked in mice homozygous for a hypomorphic
Ikaros allele [67]. This is associated with a loss of Toll-like recep-
tors 7 and 9, which are expressed by plasmacytoid dendritic cells,
and a failure to produce type-I interferons in response to Toll-like
receptor ligands [67].
In addition to directing lymphocyte differentiation and func-
tion, members of the Ikaros family have also been linked to the reg-
ulation of lymphocyte survival by controlling the expression of
Bcl2 and related proteins [68–70].
Key developmental decision such as T cell commitment [71],
marginal zone B cell differentiation [72] and the emergence of T-
cell malignancies, in particular T-ALL [73] involve signaling
through the Notch receptor. Although not restricted to the immune
system and therefore not strictly an ‘immune receptor’, Notch is
discussed here due to its special relationship with the Ikaros fam-
ily. Ikaros controls the effects of Notch signaling [74–76] at least in
part by repressing target genes of Notch signaling [75,76] and
Notch activation is an early event during T-Cell leukemogenesis
in Ikaros-deﬁcient mice [77]. The relationship between Ikaros
and Notch may be reciprocal: not only does Ikaros appear to con-
trol the Notch pathway, but Notch signaling may also impact on
Ikaros expression. For example, Notch3 has been shown to regulate
the 3’ UTR binding protein HuD, which in turn is reported to affect
the alternative splicing of Ikaros [78].5. Open questions and future directions
Given the signiﬁcant contributions of Ikaros family proteins to
normal haematopoiesis and to human leukaemia, it is of obvious
importance to identify target genes that are regulated by Ikaros
M. Merkenschlager / FEBS Letters 584 (2010) 4910–4914 4913on a genome-wide scale in developing T and B cells and in other
haematopoietic lineages. Once these target genes are known we
can begin to address how Ikaros proteins regulate cellular commit-
ment, differentiation and function.
In addition to promoting a better understanding of haematopoi-
esis, the identiﬁcation of Ikaros target genes may also guide thera-
peutic strategies. In leukaemias where the IKZF1 gene is mutated or
deleted, the loss of functional Ikaros protein results in the deregu-
lation of target genes. Pinpointing Ikaros targets that are critical for
the leukaemic state is important because they present potential
drug targets.
Finally, it will be critical to gain an understanding of how Ikaros
family members themselves are regulated, both at the transcrip-
tional level and by post-translational modiﬁcations. This will en-
able an understanding how Ikaros can act at the right time and
in the right place to regulate gene expression in a way that is fully
integrated with cell lineage, developmental stage, the cell cycle,
and extracellular signals.
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